Bladder cancer: Discussions

HCRN GU 16-257, RETAIN

ASCO GU 2023

Bladder preservation strategies - promising data but no…

P. Grivas, M.-O. Grimm, T. Powles, I. Duran, S. Chowdhury, Y. Loriot

IMvigor130, JAVELIN-Bladder100, TROPHY-U1-cohort3

ASCO GU 2023

New updates on immunocheckpoint inhibitors and ADCs -…

T. Powles, M.-O. Grimm, I. Duran, S. Chowdhury, Y. Loriot, P. Grivas

CheckMate-257

ASCO GU 2023

Robust DFS benefit, but lack of OS data leaves open…

T. Powles, L.-M. Krabbe, I. Duran, S. Chowdhury, Y. Loriot, P. Grivas

Bladder cancer - metastasized/localized

IMvigor130, CheckMate 274, UNITE

ASCO GU 2023

No change in SoC, but new genomic predictors for EV…

Joaquim Bellmunt, MD

IMvigor130

ASCO GU 2023

Atezo monotherapy for mUC

Axel S. Merseburger, MD

IMvigor 130

ASCO GU 2023

Final OS data show no significant benefit for chemo…

Tom Powles, MD

HCRN GU 16-257; IMvigor-130; TROPHY-U-01 cohort 2; JAVELIN Bladder 100

ASCO GU 2023

Re-shaping bladder cancer treatment

Ignacio Duran, MD

HCRN GU14-188

ASCO GU 2023

Benefit of neoadjuvant pembro for CE and CI patients

Peter J. Goebell, MD

IMvigor-130

ASCO GU 2023

No final OS difference - but subgroups may benefit from…

Gil Morgan, MD

KEYNOTE-057

ASCO GU 2023

Pembro for HR NMIBC

Axel S. Merseburger, MD

IMvigor130

ASCO GU 2023

IMvigor130: final OS

Axel S. Merseburger, MD

IMvigor130

ASCO GU 2023

PD-1 as combo in 1st line

Philipp Ivanyi, MD

JAVELIN Bladder

ASCO GU 2023

Update / German Real World Data M1 BC

Philipp Ivanyi, MD

Javelin Bladder 100; Trophy-U-01 Cohort 3

ASCO GU 2023

Urothelial cancer highlights from ASCO GU23

Petros Grivas, MD

IMvigor130

ASCO GU 2023

Final overall survival

Marc-Oliver Grimm, MD

Bladder cancer - NIMBC/MIBC

CheckMate 274

ASCO GU 2023

Exciting survival data for adjuvant NIVO

Tom Powles, MD

Keynote-057

ASCO GU 2023

Pembrolizumab in HR NIMBC

Tarik Esen, MD

CheckMate 274

ASCO GU 2023

Checkpoint inhibition in adjuvant therapy

Philipp Ivanyi, MD

CheckMate 274

ASCO GU 2023

3 yrs outcome of Nivo for adjuvant therapy

Marc-Oliver Grimm, MD

THOR-2

ASCO GU 2023

Urothelial cancer - hidden gems of the poster session

Tom Powles, MD

IMvigor130, CheckMate 274

ASCO GU 2023

The bladder cancer highlights of ASCO GU

Yohann Loriot, MD

CheckMate-257

ASCO GU 2023

Impressive DFS with adjuvant Nivo in biomarker-positive…

Laura-Maria Krabbe, MD

Keynote-057

ASCO GU 2023

New data for pembro in HR NIMBC

Joaquim Bellmunt, MD

Keynote-057; CheckMate 274

ASCO GU 2023

NMIBC highlights from ASCO GU23

Petros Grivas, MD

Bladder cancer 100 sec - multi language

ASCO GU 2023

Los aspectos más destacados del ASCO GU 2023 en cáncer…

Joaquim Bellmunt, MD

Keynote-057, CheckMate 274, Javelin Bladder 100, Trophy-U-01 Cohort 3

ASCO GU 2023

Επισημάνσεις για τον καρκίνο του ουροθηλίου από την…

Petros Grivas, MD

HCRN GU 16-257; IMvigor-130; TROPHY-U-01 cohort 2; JAVELIN Bladder 100

ASCO GU 2023

Refinando el tratamiento del cancere vejiga

Ignacio Duran, MD

Keynote-057

ASCO GU 2023

BCG yanıtsız yüksek riskli KİOMK tedavisinde…

Tarik Esen, MD

TRITON3

ASCO GU 2023

PARPi are effective in PCa - which subgroups benefits…

Yohann Loriot, MD

IMvigor130, CheckMate 274

ASCO GU 2023

The bladder cancer highlights of ASCO GU

Yohann Loriot, MD

Prostate cancer: Discussions

TALAPRO-2, PROpel

ASCO GU 2023

BRCA mutations in mCRPC - the importance of biomarkers…

A. Bjartell, E. Efstathiou, S. Chowdhury, A. S. Merseburger, G. Morgan

TRITON3, MAGNITUDE

ASCO GU 2023

Benefits and risks of precision medicine with PARPi

A. Bjartell, E. Efstathiou, S. Chowdhury, A. S. Merseburger, G. Morgan

ARASENS

ASCO GU 2023

Triplet combination - all-comer therapy or high risk…

S. Chowdhury, A. S. Merseburger, M.-O. Grimm, G. Morgan, A. Bjartell, E. Efstathiou

Prostate cancer - advanced/localized

ASCO GU 2023

Normal baseline testosterone level is a strong…

Tarik Esen, MD

Arasens

ASCO GU 2023

Monotherapy is not any longer standard of care

Neal Shore, MD

ASCO GU 2023

Controversy in ADT roundtable

Neal Shore, MD

NRG/RTOG

ASCO GU 2023

MMAI - a superior prognostic marker for high risk…

Tarik Esen, MD

ARASENS

ASCO GU 2023

Benefit in all groups

Gil Morgan, MD

ARASENS

ASCO GU 2023

ARASENS - post-hoc subgroup analysis

Axel S. Merseburger, MD

ASCO GU 2023

New ways to target androgen receptor signaling

Anders Bjartell, MD

FORMULA-509

ASCO GU 2023

Intensification of salvage therapy in high risk…

Peter J. Goebell, MD

ASCO GU 2023

Surgery vs. Radiation for N1 PCa: who wins?

Declan Murphy, MD

ARASENS

ASCO GU 2023

Doublet or all-in: the solution for all patients?

Axel Merseburger, MD; Anders Bjartell,MD

ARASENS; PEACE-1

ASCO GU 2023

mHSPC - new standard and more insights

Philipp Ivanyi, MD

ARASENS

ASCO GU 2023

ARASENS: triple independent of volume and risk

Peter J. Goebell, MD

Formula 509

ASCO GU 2023

Formula 509: Racing to a better straegy for…

Declan Murphy, MD

FORMULA-509

ASCO GU 2023

PARP and testing

Axel S. Merseburger, MD

Prostate cancer - mCRPC

TRITON3

ASCO GU 2023

PARPi study with different design

Anders Bjartell, MD

MAGNITUDE

ASCO GU 2023

PARPi & ARPi with wonderful data

Eleni Efstathiou, MD

TALAPRO-2; PROpel

ASCO GU 2023

PARPi combo approval for all-comers - balancing…

Axel Merseburg, MD; Anders Bartell, MD

Talapro-2

ASCO GU 2023

Tiebreaker for previous trials

Neal Shore, MD

Talapro-2

ASCO GU 2023

Encouraging results for Talazoparib

Gil Morgan, MD

TALAPRO-2

ASCO GU 2023

PARPi combo: all-comer treatment for mCRPC

Axel S. Merseburger, MD

TRITON3

ASCO GU 2023

Rucaparib: treatment option for biomarker-selected…

Gil Morgan, MD

PROpel

ASCO GU 2023

Propel - final OS

Axel S. Merseburger, MD

TRITON3

ASCO GU 2023

PARPi are effective in PCa - which subgroup benefits…

Yohann Loriot, MD

TRITON3

ASCO GU 2023

Rucaparib - ready for clinical practice in BRCAmut…

Simon Chowdhury, MD

Talapro-2

ASCO GU 2023

TALA ENZO with improved PFS in mCRPC

Tarik Esen, MD

TALAPRO-2

ASCO GU 2023

TALA in 1st line for all patients with mCRPC

Peter J. Goebell, MD

TRITON3, Talapro2, PROpel

ASCO GU 2023

PARPi combination in mCRPC

Simon Chowdhury, MD

TRITON3

ASCO GU 2023

Rucaparib - the new player?

Peter J. Goebell, MD

Prostate cancer 100 sec - multi-language

NRG/RTOG

ASCO GU 2023

MMAI- Yüksek riskli prostat kanserinde üstün bir…

Tarik Esen, MD

ASCO GU 2023

edavi öncesi normal testosteron seviyesi ADT sonrası…

Tarik Esen, MD

TRITON3

ASCO GU 2023

Ny PARP hämmar studie med anna design

Anders Bjartell, MD

ASCO GU 2023

ASCO GU 2023

Nya vägar att blockera androgenreceptor signalering

Anders Bjartell, MD

MAGNITUDE

ASCO GU 2023

PARPi & ARPi με υπέροχα δεδομένα

Eleni Efstathiou, MD

Formula 509

ASCO GU 2023

RP sonrası kurtarma RT ile GnRH Analog ABİ APA…

Tarik Esen, MD

PACE-A

ASCO GU 2023

Lokalize prostat kanserinde cerrahi ile SBRT…

Tarik Esen, MD

ASCO GU 2023

miR371'in orşiektomi sonrası tedavi seçimini…

Tarik Esen, MD

Talapro-2

ASCO GU 2023

TALA ENZA kombinasyonu ile mKDPK olan hastalarda daha…

Tarik Esen, MD

Renal cancer - Discussions

CheckMate_9ER

ASCO GU 2023

Updated data of CheckMate 9ER - impact on real-world…

T. Powels, P. Ivanyi, P. Goebell, H. Hammers, J. Bellmunt, S. K. Pal, S. Chowdhury

COSMIC-313, CaboPoint

ASCO GU 2023

Novel updates on cabozantinib in advance RCC

T. Powels, P. Ivanyi, P. Goebell, H. Hammers, J. Bellmunt, S. K. Pal, S. Chowdhury

ZIRCON

ASCO GU 2023

Theranostics in RCC - usefull tools for ccRCC?!

L.-M. Krabbe, P. Ivanyi, P. J. Goebell, H. Hammers, J. Bellmunt, S. M. Pal, S. Chowdhury

Renal cancer - 100 sec

COSMIC-313

ASCO GU 2023

Hypothesis-generating differences in risks groups

Laura-Maria Krabbe, MD

IMDC

ASCO GU 2023

Outcomes of patients with brain metastases treated with…

Philipp Ivanyi, MD

CheckMate_9ER

ASCO GU 2023

Reassuring update of CM9ER with longer follow up

Laura-Maria Krabbe, MD

CheckMate 9ER, CaboPoint

ASCO GU 2023

Longer FU confirms significant benefit of Nivo-Cabo,…

Philipp Ivanyi, MD

CaboPoint

ASCO GU 2023

First prospective data on 2nd line therapy after IO…

Laura-Maria Krabbe, MD

COSMIC-313; CheckMate_9ER

ASCO GU 2023

New therapy choices for renal cell cancer patients

Tom Powles, MD

ZIRCON

ASCO GU 2023

Zircon-PET in RCC

Simon Chowdhury, MD

Varia

ASCO GU 2023

Refining prediction of stage I seminoma

Ignacio Duran, MD

ASCO GU 2023

High accuracy of miR371 to guide treatment selection…

Tarik Esen, MD

ASCO 2023

microbiom & CPI perspectives

Philipp Ivanyi, MD

Varia - multi-language

ASCO GU 2023

Mejorando la estimacion pronostica en Seminoma Estadio…

Ignacio Duran, MD